Skip Navigation


JAC Advance Access originally published online on May 10, 2005
Journal of Antimicrobial Chemotherapy 2005 55(6):1029-1031; doi:10.1093/jac/dki151
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/6/1029    most recent
dki151v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wuthiekanun, V.
Right arrow Articles by Peacock, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wuthiekanun, V.
Right arrow Articles by Peacock, S. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei

Vanaporn Wuthiekanun1, Allen C. Cheng1,2, Wirongrong Chierakul1, Premjit Amornchai1, Direk Limmathurotsakul1, Wipada Chaowagul3, Andrew J. H. Simpson4, Jennifer M. Short5, Gumphol Wongsuvan1, Bina Maharjan1, Nicholas J. White1,6 and Sharon J. Peacock1,6,*

1 Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 2 Menzies School of Health Research, Charles Darwin University and Northern Territory Clinical School, Flinders University, Darwin, Australia; 3 Medical Department, Sappasithiprasong Hospital, Ubon Ratchathani, Thailand; 4 Biomedical Sciences, DSTL, Salisbury; 5 Department of Infection and Tropical Medicine, Heartlands Hospital, Birmingham; 6 Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK

* Corresponding author. Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok, 10400, Thailand. Tel: +66-2-354-9172; Fax: +66-2-354-9169; Email: sharon{at}tropmedres.ac

Objectives: Trimethoprim/sulfamethoxazole is commonly used to treat melioidosis. Antimicrobial susceptibility testing using the disc diffusion method is commonly used in melioidosis-endemic areas, but may overestimate resistance to trimethoprim/sulfamethoxazole.

Patients and methods: We performed disc diffusion and Etest on isolates from the first positive culture for all patients presenting to Sappasithiprasong Hospital, Ubon Ratchathani, Thailand, with culture-confirmed melioidosis between 1992 and 2003.

Results: The estimated resistance rate for 1976 clinical Burkholderia pseudomallei isolates was 13% by Etest and 71% by disc diffusion. All isolates classed as either susceptible (n=358) or as having intermediate resistance (n=218) on disc diffusion were susceptible by Etest. Only 258 of the 1400 (18%) isolates classed as resistant on disc diffusion were resistant by Etest.

Conclusions: Disc diffusion testing of B. pseudomallei may be useful as a limited screening tool in resource poor settings. Isolates assigned as ‘susceptible’ or ‘intermediate’ by disc diffusion may be viewed as ‘susceptible’; those assigned as ‘resistant’ require further evaluation by MIC methodology.

Keywords: Burkholderia pseudomallei , melioidosis , susceptibility , Etest


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. C. Cheng, E. S. McBryde, V. Wuthiekanun, W. Chierakul, P. Amornchai, N. P. J. Day, N. J. White, and S. J. Peacock
Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis
Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4193 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Thamlikitkul and S. Trakulsomboon
In Vitro Activity of Doripenem against Burkholderia pseudomallei
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 3115 - 3117.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
V. Thamlikitkul and S. Trakulsomboon
In vitro activity of ceftobiprole against Burkholderia pseudomallei
J. Antimicrob. Chemother., February 1, 2008; 61(2): 460 - 461.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. P. Sivalingam, S. H. Sim, L. T. Aw, and E. E. Ooi
Antibiotic susceptibility of 50 clinical isolates of Burkholderia pseudomallei from Singapore
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1102 - 1103.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Thamlikitkul and S. Trakulsomboon
In Vitro Activity of Tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1555 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
W. Chaowagul, W. Chierakul, A. J. Simpson, J. M. Short, K. Stepniewska, B. Maharjan, A. Rajchanuvong, D. Busarawong, D. Limmathurotsakul, A. C. Cheng, et al.
Open-Label Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Doxycycline, and Chloramphenicol Compared with Trimethoprim-Sulfamethoxazole and Doxycycline for Maintenance Therapy of Melioidosis
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4020 - 4025.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.